Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...

Ahead of a Senate hearing next week at which Novo Nordisk’s CEO has been called to testify, health committee chair Bernie Sanders is keeping the heat on the company. Since April of this year ...

Sept 17 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve more than 13% weight loss, but that has been over much longer time ...

Tammy is co-anchor on Action 2 News This Morning and Consumer First Alert reporter. She joined WBAY in 2012 as co-anchor of Action 2 News This Morning with Kevin Rompa. Tammy began her journalism ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...